Canada's Spectral Medical Q2 revenue falls on lower reagent sales

Spectral Medical

07/08/2026 12:41

Overview
Canada theranostic firm's Q2 2026 revenue fell 24% yr/yr due to lower reagent sales
Company posted a quarterly gain, driven by decreased operating expenses and fair value adjustments
Spectral completed FDA PMA application for PMX and advanced to substantive review process

Outlook
Spectral is focused on supporting FDA review and preparing for potential PMX commercialization
Company says market readiness efforts are aligned with potential FDA approval timelines
Spectral continues to evaluate financing options to fund operations beyond PMX commercialization

Result Drivers
REAGENT SALES DROP - Co said lower reagent sales and reduced service revenue after sub study conclusion drove Q2 revenue decline
OPERATING EXPENSES FALL - Co attributed sharp drop in operating expenses to fair value adjustment on derivative liabilities and decreased consulting fees as trial activities wound down
TRIAL WIND-DOWN - Co said clinical development and regulatory costs fell as Tigris trial activities and clinical site closures reduced consulting and professional fees

Company press release: ID:nGNX1h5xqX

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
C$621,000
C$604,000 (1 Analyst)

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Spectral Medical Inc is C$3.15, about 125% above its August 6 closing price of C$1.40

Reuters Recommended Reads
Aug 6 - Canada's Profound Medical Q2 loss shrinks on lower costs, revenue hit by shipment timing
Aug 6 - CytoSorbents Q2 adjusted loss narrows on cost controls
Aug 5 - Standard BioTools Q2 revenue falls on consumables weakness

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)